CONFERENCE UPDATES: ASH 2021
Blinatumomab as a new option for reinduction therapy with children and AVAs in low-risk first relapse of B-ALL
28 Jan 2022
CONFERENCE UPDATES: ASH 2021
Blinatumomab as a new option for reinduction therapy with children and AVAs in low-risk first relapse of B-ALL